EpiWatch, Inc. Announces Publication of Landmark Phase III Study in Neurology Open Access
Apple Watch®–based tonic clonic seizure detection for ages 5 and up demonstrates high seizure detection accuracy with low False Alarm Rate (FAR).
BALTIMORE, MD, UNITED STATES, May 28, 2026 /EINPresswire.com/ — EpiWatch today announced the publication of its Phase III clinical study in Neurology Open Access, demonstrating strong performance of its Apple Watch–based seizure detection application in identifying tonic-clonic seizures (TCS) across pediatric and adult populations ages 5 and up.
Over 3.5 million Americans are impacted by epilepsy. Injury related to seizures and Sudden Unexpected Death in Epilepsy (SUDEP) remain critical risks for individuals with uncontrolled or poorly controlled seizures—especially those who sleep alone. Recent clinical guidelines published by the International League Against Epilepsy (ILAE) recommend consideration of wearable devices for tonic clonic seizure detection and alerting to help reduce this risk.
